Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem Q3 Revenues Rise 6 Percent

NEW YORK (GenomeWeb) – Enzo Biochem said on Monday that its revenues for its fiscal third quarter were up 6 percent year over year.

For the three months ended April 30, the company reported total revenues of $24 million, up from $22.6 million in the year-ago quarter. Enzo's Clinical Labs segment revenues rose to 9 percent $14.5 million from $13.4 million, while Life Science product revenues increased 5 percent to $8.7 million from $8.3 million. Royalty and licensing fee income slid to $729,000 from $949,000.

In a statement, Enzo President Barry Weiner said that the company benefitted from its program to emphasize higher value services and products, as well as efforts to reduce overhead and costs.

Weiner added that the market for Life Sciences products is still feeling the effects of reduced government grants and expenditures, but has also shown improvement on the research front.

Enzo sharply narrowed its net loss in Q3 to $455,000, or $.01 per share, from a net loss of $5.8 million, or $.15 per share, a year ago. Enzo said that the results for the recently completed quarter included a settlement net of $3.1 million with Affymetrix, which was offset by a legal settlement reserve of about $2 million related to a US Department of Justice investigation into Enzo Clinical Labs processes in the collection of diagnosis codes from physicians.

Excluding those amounts, associated legal fees, and one-time separation costs, the company had a net loss of $.05 per share on a non-GAAP basis, Enzo said.

The firm finished the quarter with $14.8 million in cash and cash equivalents.